---
layout: post
date: 2026-01-22
title: "[ë…¼ë¬¸ë¦¬ë·°] Distinct neuroimaging subtypes of ADHD among adolescents based on semi-supervised learning"
tags: [ADHD, GAN]
categories: [Paper Review]
---


## Abstract

- ADHDëŠ” ì†Œì•„ê¸°ì— ë°œë³‘í•˜ëŠ” neurodevelopmental disorder(ì‹ ê²½ ë°œë‹¬ ì¥ì• )ë¡œ, ì§„ë‹¨ê³¼ ì•„í˜• ë¶„ë¥˜ê°€ ì„ìƒì  íŠ¹ì„±ì— ê¸°ë°˜í•´ ì£¼ê´€ì ì´ë©° ì‹ ë¢°ì„± ë¶€ì¡±.
- ì„ìƒì  subtype ë¶„ë¥˜ëŠ” ì˜ˆí›„ì— ëŒ€í•œ ëª…í™•í•œ ì§€í‘œ ì œê³µ X

_â†’ __**Semi-Supervised Learning**__ ê¸°ë°˜ì˜ heterogenity íŒŒì•… method ì œì‹œ_

- Adolescent Brian Cognitive Development (ABCD) ë°ì´í„° í™œìš©
- ì •ìƒêµ° ëŒ€ë¹„ Cortical Thicknessë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì„¸ ê°€ì§€ subtype í™•ì¸ â†’ ì €ë°œë‹¬(lower CT)/ê³¼ë°œë‹¬(higher CT)/í˜¼í•©
	- `ì €ë°œë‹¬êµ°` : cognitive score ìœ ì˜ë¯¸í•˜ê²Œ ë‚®ê³  ì‚¬íšŒê²½ì œì  ì§€ìœ„ ì¢‹ì§€ ì•ŠìŒ
	- `ê³ ë°œë‹¬êµ°` : ê°ì„±ì œ ì•½ë¬¼(stimulant medication) ë°˜ì‘ ì•ˆì¢‹ìŒ
- Gene expressions / Neurotransmitter distributions (ìœ ì „ì ë°œí˜„ / ì‹ ê²½ ì „ë‹¬ ë¬¼ì§ˆ ë¶„í¬)
	- `ì €ë°œë‹¬/í˜¼í•©êµ°` : ë„íŒŒë¯¼ ë° í¥ë¶„ì„± ê²½ë¡œì˜ upregulation(ìƒí–¥ ì¡°ì ˆ) ê°•í•¨

		> ğŸ’¡ **Upregulation** : íŠ¹ì • ì‹ í˜¸/ìê·¹ì— ë°˜ì‘í•´ ì„¸í¬ ë‚´ íŠ¹ì • ë¬¼ì§ˆ(ìˆ˜ìš©ì²´, ë‹¨ë°±ì§ˆ ë“±)/ë°œí˜„ ì¦ê°€í•˜ëŠ” í˜„ìƒ


			_â†’ ì‹ í˜¸/ìê·¹ì— ëŒ€í•œ ë¯¼ê°ì„±ì„ ë†’ì´ê¸° ìœ„í•œ ë°˜ì‘_

	- `ê³ ë°œë‹¬êµ°` : ì•½í•¨

	_â†’ ê°ì„±ì œ ì•½ë¬¼ì— ëŒ€í•œ ë°˜ì‘ì„± ì°¨ì´ ì„¤ëª… ê°€ëŠ¥ (ê³ ë°œë‹¬êµ°ì—ì„œ í¥ë¶„ì„± ê²½ë¡œì˜ upregulation ì•½í•¨, ì €ë°œë‹¬/í˜¼í•©êµ°ì—ì„œ ë†’ìŒ)_


---


---



## Introduction


DSM-5(Diagnostic and Statistical Manual of Mental Disorder, fifth edition)ì— ë”°ë¥´ë©´ ADHDëŠ” ì„¸ ê°€ì§€ì˜ ì„ìƒ í‘œí˜„í˜•ìœ¼ë¡œ ë‚˜ë‰¨

- `Redominantly inattentive (ADHD-I)` : ì£¼ì˜ë ¥ ê²°í•
- `Predominantly hyperactive/impulsive (ADHD-H/I)` : ê³¼ì‰ í–‰ë™/ì¶©ë™ì„±
- `Combined (ADHD-C) presentations` : ë³µí•©í˜•

_â†’ ì„ìƒ ì¦ìƒì„ ì´ìš©í•œ ë¶„ë¥˜ëŠ” ì˜ˆí›„ì™€ ê´€ë ¨ì„± ë‚®ìŒ_


<span class="notion-red">_â†’ ë‚®ì€ ê°•ê±´ì„±, ì•½ë¬¼ ë°˜ì‘ êµ¬ë³„ ë¶ˆê°€, ë™ë°˜ ì§ˆí™˜, ê³µìœ ë˜ëŠ” neuropsychological(ì‹ ê²½ì‹¬ë¦¬í•™ì ) ê²°ì†, ì‹ ê²½ìƒë¬¼í•™ì  ê¸°ì € ë°˜ì˜ ë¶ˆê°€ ë¬¸ì œ_</span>


MRIë¥¼ ì´ìš©í•œ ì—°êµ¬ë“¤ì´ ì§„í–‰ë˜ì–´ ì™”ìœ¼ë‚˜ ì¼ê´€ì„± ì—†ëŠ” ê²°ê³¼ë¥¼ ë³´ì„

- ê¸°ì¡´ ì—°êµ¬ë“¤ì€ hierarchical clustering, K-means, Bayesian ê°™ì€ unsupervised clustering ìœ„ì£¼

	â†’ í™˜ì ë°ì´í„°ì—ë§Œ ì˜ì¡´í•´ clustering


_**â‡’ Semi-supervised learningì„ ì´ìš©í•´ ì •ìƒêµ° ê³ ë ¤**_

	- Smile-GAN ì°¨ìš© _(Yang et al., 2021)_
	- data distributionê³¼ data transformì˜ linearity ê°€ì •ì— ì˜ì¡´í•˜ì§€ ì•ŠìŒ

		> ğŸ’¡ **Not rely on Assumptions?**

			- ì…ë ¥ ë°ì´í„°ë“¤ì´ Gaussian distributionê³¼ ê°™ì€ íŠ¹ì • ë¶„í¬ë¥¼ ë”°ë¥¸ë‹¤ê³  ê°€ì •í•˜ì§€ ì•ŠìŒ
			- í™˜ì ë°ì´í„°ê°€ ì •ìƒì—ì„œì˜ ì„ í˜• ë³€í™˜(NC + noise)ìœ¼ë¡œ ê°€ì •í•˜ì§€ ì•ŠìŒ

		<span class="notion-red">_**â†’ Smile-GANì€ data ìì²´ì˜ **_</span><span class="notion-red">_**ë¹„ì„ í˜• êµ¬ì¡°**_</span><span class="notion-red">_**ë¥¼ í•™ìŠµ**_</span>


**ì—°êµ¬ ë‚´ìš©**

- Smile-GANì„ ì´ìš©í•´ ABCD cohortì— ëŒ€í•´ Cortical Thickness ë¶„ì„
	- Subtype ë¶„ë¥˜
	- ì„ìƒ ë°œí˜„/í™˜ê²½ ìš”ì¸/ì¹˜ë£Œ ë°˜ì‘ ì¡°ì‚¬
- ì™¸ë¶€ ë°ì´í„°ì…‹ì— subtype ì ìš©/ê²€ì¦

---


---



## Materials and Method



### Materials



#### Participants


DSM-5 ê¸°ë°˜ ì§„ë‹¨, _Kiddie-Schedule of Affective Disorders and Schizophrenia for DSM-5 (KSADS-COMP) â†’ ì¸í„°ë·° ê¸°ë°˜ì˜ ADHD ì¦ìƒ ìˆ˜ì¹˜(ê°œìˆ˜)_

- Schizophrenia(ì •ì‹ ë¶„ì—´ì¦), bipolar disorder(ì–‘ê·¹ì„± ì¥ì• ), ì¶”ì • IQ < 70 ì œì™¸

**ABCD**

- `Baseline` : ADHD/HC, 929/5580
	- age 9.83 Â± 0.50 years, 68.7% male for ADHD
	- age 9.97 Â± 0.62 years, 52.0% male for HC
- `2 year(follow-up)` : 633/4219
	- age 11.96 Â± 0.58 years, 69.8% male for ADHD
	- age 11.90 Â± 0.59 years, 53.2% male for HC

**ADHD-200 (external)**

- `Baseline` : 330/414
	- age 11.67 Â± 3.02, 78.2% male for ADHD
	- age 11.67 Â± 2.89 years, 53.0% male for HC

---



#### Image pre-processing and quality control


**ABCD**

- FreeSurfer ì´ìš©í•œ cortical reconstruction, segmentation pipeline ìˆ˜í–‰

	_â†’ DAIRCì—ì„œ ì œê³µí•œ ì „ì²˜ë¦¬ëœ íŒŒì¼ ì‚¬ìš©_

- Destrieux template ì ìš©
- Neuro-Combat ì´ìš©í•œ site-specific variations estimation/regression

	> ğŸ’¡ **Site-specific variations estimation/regression?**

		- ì¥ë¹„/ìŠ¤ìº” site ì°¨ì´ë¡œ ì¸í•œ í¸ì°¨(site effect)ë¥¼ ì¶”ì •í•´(estimation) ì œê±°/ì¡°ì •(harmonization)

**ADHD-200**

- NITRC ì´ìš©í•œ ìœ ì‚¬ ê³¼ì • ìˆ˜í–‰
- Destrieux template ì ìš©, parcellate the brain into 148 ROIs

---



### Analysis



#### Semi-supervised classification


**Smile-GAN**

- nonlinear semi-supervised DL algorithm
- GAN ì´ìš©í•œ ì •ìƒê°’ìœ¼ë¡œë¶€í„° í™˜ì ë°ì´í„° í•©ì„±
- Adversarial learningì„ í†µí•œ í•©ì„±/ì‹¤ì œ ë°ì´í„° êµ¬ë³„ ë¶ˆê°€í•˜ë„ë¡ í•¨

**Input**

- `HC` : í‰ê·  1, í‘œì¤€ í¸ì°¨ 0.1ë¡œ ì •ê·œí™”
- `ADHD` : HCì— ëŒ€í•´ Z-score normalize (HC ê·¸ë£¹ì˜ í‰ê· /í‘œì¤€ í¸ì°¨ ì´ìš©)

**Subtype ìˆ˜ ê²°ì •**

- Adjusted Random Indexì™€ permutation test ì§„í–‰
- 2-7ê°œì˜ cluster ë¶„í• ì— ëŒ€í•´ ê°ê° 5-fold cross-validation ìˆ˜í–‰

<span class="notion-red">_â†’ 3ê°œ clusterì— ëŒ€í•´ì„œë§Œ p-value < 0.05 ë¡œ ìœ ì˜ë¯¸_</span>


_ë¶„ì„ ê²°ê³¼ ê²€ì¦ì„ ìœ„í•´ ê° subtypeì—ì„œ main resultì™€ validation datasetê°„ì˜ T-score spatial correlationì„ ì¡°ì‚¬_


(Main result : ABCD; validation dataset : ADHD-200)


---



#### Imaging-transcriptome analysis


Subtypeì˜ genetic signature ë¶„ì„ì„ ìœ„í•´ Allen Human Brain Atlas (AHBA) microarray dataset ì‚¬ìš©

- 6ê°œ sampleì˜ left hemisphere transcriptome data ì‚¬ìš©
- í‘œì¤€ ì „ì²˜ë¦¬ ìˆ˜í–‰ (probe-to-gene annotation ì‹ë³„/filtering/brain region assign/scaled robust sigmoid transformation) 

	â†’ Destrieux template êµì°¨ í›„ 72ê°œ ROIì— ëŒ€í•´ 10,027 gene expression íšë“

- RNA expressionê³¼ T stastics ê°„ì˜ correlation ë¶„ì„

_â†’ ê° Subtypeê³¼ ë†’ì€ correlation ë³´ì´ëŠ” gene ì‹ë³„_


---



#### Imaging-neurochemical analysis

- 3ê°€ì§€ì˜ neurotransmitter systemì— ê±¸ì¹œ 5ê°œì˜ receptor ë¶„ì„ (JuSpace ì´ìš©)
- Neurochemical density mapì€ prior PET/SPECT ì—°êµ¬ì—ì„œ ì°¨ìš©
	- MNI templateì— ì •ë ¬ë˜ì–´ Destrieux atlas ë”°ë¼ 148ê°œ ROIë¡œ ë¶„í• 
- Neurochemical density mapê³¼ subtypeì˜ T stastics mapì˜ spatial correlation ë¶„ì„

<span class="notion-red">_â†’ Subtype ë³„ neurochemical pattern ë¶„ì„_</span>


---



### Statistical analysis

- Subtype ë¶„ì„ ì „ follow-up ë°ì´í„°ì— ëŒ€í•´ ê³µë³€ëŸ‰ ì œì–´ (age, sex, site, race, ethnicity, socioeconomic status, and birth maternal conditions)
	- ADHD-200ì˜ ê²½ìš° age, sex, site ë§Œ í†µì œ
- Smile-GAN ì´ìš©í•œ subtyping í›„ two-sample T-test
	- psychopathology(ì •ì‹ ë³‘ë¦¬), disease-related symdromes(ê´€ë ¨ ì¦í›„êµ°), and socioeconomic status(ì‚¬íšŒê²½ì œì  ì§€ìœ„) ë¹„êµ
- Disease treatment ë°˜ì‘ ë¹„êµ ìœ„í•´ baseline ë¶€í„° follow-up ê¹Œì§€ì˜ ì§„ë‹¨ëª… ë³€í™”ë¥¼ T-test ì´ìš©í•´ ë¶„ì„

---


---



## Result



#### Distinct neuroimaging subtypes of ADHD


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/ad4df74c-7cbe-4465-ac72-71345219e411/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB466XDR3HB7W%2F20260221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260221T091715Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEN%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJHMEUCIQDSlRR09cmRCl4w4M%2BS15td384MzF%2FyFkQOfv8jMxPBeAIgKaZaj4xYt%2BsilOCUEYb1HCQQC85klW%2BLRnmRGR6gv5MqiAQIp%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAAGgw2Mzc0MjMxODM4MDUiDCvRT0OFOY%2BkM2Bp3CrcA2N0Oz5v2htk04oynOtwLHgpZxcOXkUUezY1sUCSp27o4crd2uoC54csM1IdsWojAWyitsTXu%2BmvwnguRx8jJoKxFg%2B9RrI9abdc%2BiNM4VU8lRqxTLkOEMivdwHu%2BybjMef02deKf3ZWzbh2h4Sp8AzeabE4Rl9QBKL1oaCCDnSqjmyiorsc2BD0Lm6n%2BVlg25uQU5lkmpYLlXYCNF%2ByaT4avTkr1a852xqNjbqqxeTcqwJuk0ux5ak8jTIt%2BQ07uneuQcz297%2BuZbU2vbPeecJAQFzjweOvMLYxOt4XCC3OgV01XNtPVOtFNoE2wNCfVuJcy1Ae1x1z7sIL%2F9ifWwTGUnbQsWgdgg1BCt8ATQxvDjQkARZF9L4LTJfxCakVU3Q2ORoeQ7W75tMXNh5zwj9R3I%2BRUoABwXyWbdsUpW85S4dbKN%2FQoKgsRqHtJ8Yr%2BUctTSJN70InmOTmqkl0QUmHDumUWvG%2FxCoUeUJ9CW2Ti5gEyWZqheEYppPffSrgxA%2F8GqaDNz5VlmpBXQAtBH1mXQ5DXv6OkoM6ifPuiWElrUBhnWHZFntcrDnJudQ%2BbAMG28yJOOpfeqtMolz87%2FEf27K6rCt5EOuLlVxpNfam0N2ur3WpUQIYbnxXMKGd5cwGOqUBui6%2FlyEta%2FP2D%2BiJ5fI9Y59kyla7yfs4GazqRsUj8hTuH%2F5dVo0oD6QaMsgR1UKEb%2B4yOqyPXIMFUIBhEdZ6Y6A3YylfI70lzLmQd7zUceQv7JzQ5oFwM1yhXYV8myUQroa4K1y39fsk221ZKHlrGZLJc4WdHBpPc1t6o3FwRCXa%2FqB5nSkKU%2B%2F1k9Tr2re%2FfPLOd%2FXpBvRGft%2BKNxG9NOPQZDtD&X-Amz-Signature=174e825c47f105b63f13c9381a1904f0b44c891e427cdad40493ff2d84628f64&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)


Cortical thicknessë¥¼ ì…ë ¥ìœ¼ë¡œ 3ê°€ì§€ Subtypeë¡œ ë¶„í• 

- `Under-developed(Lower CT)` : posterior regionì— ë‚®ì€ CT ë³´ì„
- `Over-developed(High CT)` : posterior regionì— ë†’ì€ CT ë³´ì„
- `Mixed subtype` : dorsal, prefrontal, posterior regionì— ë†’ì€ CT, temporalì—ëŠ” ë‚®ì€ CT ë³´ì„

_â†’ ë…ë¦½ ë°ì´í„°ì¸ ADHD-200ì—ì„œë„ ì¼ê´€ì ì¸ ê²°ê³¼ ë³´ì„_


---



#### Neuroimaging subtypes encompassed differential clinical, family, and social characteristics


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/1a1d4829-9137-4ff7-8c14-b80f0100c690/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB466XDR3HB7W%2F20260221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260221T091715Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEN%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJHMEUCIQDSlRR09cmRCl4w4M%2BS15td384MzF%2FyFkQOfv8jMxPBeAIgKaZaj4xYt%2BsilOCUEYb1HCQQC85klW%2BLRnmRGR6gv5MqiAQIp%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAAGgw2Mzc0MjMxODM4MDUiDCvRT0OFOY%2BkM2Bp3CrcA2N0Oz5v2htk04oynOtwLHgpZxcOXkUUezY1sUCSp27o4crd2uoC54csM1IdsWojAWyitsTXu%2BmvwnguRx8jJoKxFg%2B9RrI9abdc%2BiNM4VU8lRqxTLkOEMivdwHu%2BybjMef02deKf3ZWzbh2h4Sp8AzeabE4Rl9QBKL1oaCCDnSqjmyiorsc2BD0Lm6n%2BVlg25uQU5lkmpYLlXYCNF%2ByaT4avTkr1a852xqNjbqqxeTcqwJuk0ux5ak8jTIt%2BQ07uneuQcz297%2BuZbU2vbPeecJAQFzjweOvMLYxOt4XCC3OgV01XNtPVOtFNoE2wNCfVuJcy1Ae1x1z7sIL%2F9ifWwTGUnbQsWgdgg1BCt8ATQxvDjQkARZF9L4LTJfxCakVU3Q2ORoeQ7W75tMXNh5zwj9R3I%2BRUoABwXyWbdsUpW85S4dbKN%2FQoKgsRqHtJ8Yr%2BUctTSJN70InmOTmqkl0QUmHDumUWvG%2FxCoUeUJ9CW2Ti5gEyWZqheEYppPffSrgxA%2F8GqaDNz5VlmpBXQAtBH1mXQ5DXv6OkoM6ifPuiWElrUBhnWHZFntcrDnJudQ%2BbAMG28yJOOpfeqtMolz87%2FEf27K6rCt5EOuLlVxpNfam0N2ur3WpUQIYbnxXMKGd5cwGOqUBui6%2FlyEta%2FP2D%2BiJ5fI9Y59kyla7yfs4GazqRsUj8hTuH%2F5dVo0oD6QaMsgR1UKEb%2B4yOqyPXIMFUIBhEdZ6Y6A3YylfI70lzLmQd7zUceQv7JzQ5oFwM1yhXYV8myUQroa4K1y39fsk221ZKHlrGZLJc4WdHBpPc1t6o3FwRCXa%2FqB5nSkKU%2B%2F1k9Tr2re%2FfPLOd%2FXpBvRGft%2BKNxG9NOPQZDtD&X-Amz-Signature=2de0034cf77e3ecfae577e713f1805977781851e3230ab4ecd6fa3e6c36e20e2&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)


Subtypeê³¼ ì„ìƒì  ê´€ì°°ì˜ ê´€ë ¨ì„± ì¡°ì‚¬ â†’ cognitive function, social behavior ì°¨ì´ ë³´ì„

- `Socioeconomic status` 
	- `Under-developed` : ë‚®ì€ ê°€ê³„ ìˆ˜ì…, ë¶€ëª¨ êµìœ¡ ìˆ˜ì¤€, ì´ë¥¸ ì‚°ëª¨ ì¶œì‚° ì—°ë ¹ / ë‹¤ë¥¸ subtype ëŒ€ë¹„ ë‚®ì€ psychopathologyì™€ cognition ìˆ˜ì¤€ ë³´ì„

<span class="notion-red">_â†’ ì¶”ê°€ë¡œ Neuroimaging subtypeê³¼ symptom-based subtypeì˜ ì—°ê´€ì„± ë¶„ì„í–ˆìœ¼ë‚˜ ê´€ë ¨ì„± íŒŒì•… ëª»í•¨_</span>


---



#### Differential response to stimulant medication among subtypes


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/310413de-9325-4f0f-929a-09869ea77609/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB4664CYFHLK6%2F20260221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260221T091717Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEN%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJGMEQCIC3kJTmJphDNbGIJW3yrJLeiNU3qMj8uyhVJqyHEYq52AiBepVjs%2Bcy5j%2Bxtb9h5R0CcBUa%2B3K%2BKCxQQeu%2B8STT%2FsyqIBAin%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAAaDDYzNzQyMzE4MzgwNSIMJMoSWQqvp8PAfyiKKtwDdekljOY%2B7aZb%2F5dJpTChimF%2FN5YZlRCZd52PKYpKHrvuaIC8h0e7R4Aq7xMBiQQS%2B6HUvY%2B%2BkYNgJfczzvDL4HlnSl2IKbZ5jUh8h%2Flq0GvC3uxZINMdKPs99eaKjEwytLJObAi3RDzNrsOGJB8x2JP%2FtCIIPiWDhFi78YY3%2B2Wug888WpeCJ6SFFLasFxm%2F6Gg6A0XBpBLsDJuWv93QhrKI6LNA2uefKq0SzwrG3K6Tov4y3eoqmF5vQYa6GKsVYvb0WNTJpPKuGqD5Q0mv23Akfim5CO6R99%2FMtqqKmSDAfjD54KHQaDbCkonA8MQQ9zgf5zFntIkNFoHWJ9xSlT7%2FRKOGnW3L5U3vh75%2BQGXIMi7Q9%2FNYpRttdXyBf1yofoTlNrjLNSobdZSyY5saZt6iXNrX16%2FaVW%2FF2ru101DE1AUkLKJjcLXnN9KFtB04TgNtNnv%2Bp%2BBv57qDU0Yh6wZAQmvTxfnXgw0sXdtcN6cN7aqUy%2BF%2FQ4L8exbR0DaetmxloeW6KF6vtnrM9Z%2BD9AHplRmi1xcaqxNB6yb2QQ5LGJOrKqj4S%2BtWCSpAAnudUrWAZ2aiWltFKr3Fa9u0iJ3jjKOlcmiozqKvBjKCEzj%2BpGgpfTZId6hvk2EwxJ3lzAY6pgEyMc8aEPmwt4Fw1uhyGEsF%2F9ZzNYiTrXXTCRs7OekfaeS1ZK4qampwgjyxWoMsCs%2F4P4EYsbdrradM2USAH3OUhJ0YDDhRcU1UJZLOaK96s8XdJqCoWt%2F9j%2BqxugkRRPsC6R0DN1M5XIQmB6Ksc0NIWGQ9ci%2Blw93e34N7MvJoHf8yZHicRNhd1bzhZxVBoLUxvjKFDqOo%2F%2BrLMptiVsevw8YbBObw&X-Amz-Signature=9d7e4089c3c663e5aeb389a6b187550d0f0112fea9306b8c7569868f2a18ed32&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)


Subtype ë³„ ê°ì„±ì œ ì•½ë¬¼ ë°˜ì‘ì„± í™•ì¸

- Methylphenidate Derivative(MPH), Amphetamine (AMPH)
- ë‘ ì•½ë¬¼ì€ ADHDì˜ 1ì°¨ ì¹˜ë£Œì œ

**ë¶„ì„ ì§€í‘œ**

- `ADHD severity` : change of CBCL-ADHD t-score at DSM-5 scale, Î”CBCL-ADHD
- `Disease symptoms` : change of KSADS-COMP ADHD diagnostic symptom number, Î”KSADS

<span class="notion-red">_â†’ Baselineì—ì„œì˜ severityì™€ symptomì´ ìœ ì‚¬í–ˆìŒì—ë„ ê°ì„±ì œ íˆ¬ì•½ í›„ subtype ë³„ íšŒë³µ ì •ë„ëŠ” ì°¨ì´ ë³´ì„(High-developed ì˜ ê²½ìš° ì•½ë¬¼ ë°˜ì‘ ì•½í•¨, under-developedê°€ ë‚˜ì€ íšŒë³µë¥  ë³´ì„)_</span>


<span class="notion-red">_â†’ ì•½ë¬¼ ë¯¸íˆ¬ì—¬êµ°ì— ëŒ€í•´ subtype ë³„ë¡œ ìœ ì˜ë¯¸í•œ ì°¨ì´ ì—†ìŒ_</span>


---



#### Distinct transcriptomic signatures among the subtypes


**RNA expression data(AHBA transcriptome dataset)ì™€ CT T-mapì˜ correlation ë¶„ì„**

- Subtypeì˜ genetic basis ì¡°ì‚¬
- Bonferroni correction ì‚¬ìš©
- `Under-developed` : 1063/1335 (pos/neg)
- `Over-developed` : 1120/713
- `Mixed` : 315/534

**Subtype ë³„ ìƒìœ„ 300ê°œ gene ì´ìš©í•´ Enrichment ë¶„ì„**

- Gene Ontology/Kyoto Encyclopedia of Genes and Genomes (KEGG) database ê¸°ë°˜
- FDR correction ì‚¬ìš©
- `Underâ€‘developed`
	- GO/KEGGì—ì„œ ë‹¤ìˆ˜ì˜ ì‹ ê²½ì „ë‹¬ ê´€ë ¨ í•­(term) í’ë¶€
	- GABAergic synapse, dopaminergic synapse, glutamatergic synapse, regulation of dopamine secretion ë“±.

	_â†’ í•´ë‹¹ subtypeì˜ CT íŒ¨í„´ê³¼ ì¼ì¹˜í•˜ëŠ” ìœ ì „ìë“¤ì´ ë„íŒŒë¯¼Â·GABAÂ·ê¸€ë£¨íƒì‚° ê²½ë¡œì™€ ë°€ì ‘í•˜ê²Œ ì—°ê²°ë˜ì–´ ìˆì–´, neurotransmitter ë¶ˆê· í˜•(ë˜ëŠ” ë³€ì¡°)ì´ êµ¬ì¡°ì  ì°¨ì´ë¥¼ ë°˜ì˜í•  ê°€ëŠ¥ì„± ì¡´ì¬_

- `Mixed`
	- GABAergic ë° glutamatergic ê´€ë ¨ í•­ì´ í’ë¶€

	_â†’ ì‹ ê²½ì „ë‹¬ì²´ê³„ ê´€ë ¨ ê¸°ì „ì´ ê´€ì—¬ëœë‹¤ëŠ” ì ì—ì„œ underâ€‘developedì™€ ìœ ì‚¬_

- `Overâ€‘developed`
	- ì‹ ê²½ì „ë‹¬ ê´€ë ¨ë³´ë‹¤ëŠ” ëŒ€ì‚¬/ì¸ìŠë¦° ê´€ë ¨ í•­(e.g. regulation of insulin secretion)ì´ ìœ ì˜í•˜ê²Œ í’ë¶€

	_â†’ Neurotransmitter ê²½ë¡œë³´ë‹¤ëŠ” ëŒ€ì‚¬ì  (insulin/ë¹„ë§Œ ê´€ë ¨) ìœ ì „ì  ê¸°ì§ˆê³¼ ì—°ê´€ë  ìˆ˜ ìˆê³ , ì´ëŠ” ì„ìƒì ìœ¼ë¡œ ë¹„ë§ŒÂ·ëŒ€ì‚¬ ì—°ê´€ì„±ìœ¼ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆìŒ_


_â†’ Subtype ê°„ ëšœë ·í•œ ìœ ì „ì  íŠ¹ì„± ì¡´ì¬_


_â†’ Under-develoepd/Mixed subtypeì˜ ê²½ìš° neurotransmitter ê´€ë ¨ ìœ ì „ì  ë¿Œë¦¬ ê°€ì§_


_â†’ Over-developedì˜ ê²½ìš° comorbid(insulin) ìœ ì „ì  ë¿Œë¦¬ ê°€ì§_


**ADHD ê´€ë ¨ ìœ ì „ì ë¶„ì„ (TWAS ê¸°ë°˜ í›„ë³´)**


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/b9862833-4ef6-427e-a2a2-58f10552bfbe/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB4664CYFHLK6%2F20260221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260221T091718Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEN%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJGMEQCIC3kJTmJphDNbGIJW3yrJLeiNU3qMj8uyhVJqyHEYq52AiBepVjs%2Bcy5j%2Bxtb9h5R0CcBUa%2B3K%2BKCxQQeu%2B8STT%2FsyqIBAin%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAAaDDYzNzQyMzE4MzgwNSIMJMoSWQqvp8PAfyiKKtwDdekljOY%2B7aZb%2F5dJpTChimF%2FN5YZlRCZd52PKYpKHrvuaIC8h0e7R4Aq7xMBiQQS%2B6HUvY%2B%2BkYNgJfczzvDL4HlnSl2IKbZ5jUh8h%2Flq0GvC3uxZINMdKPs99eaKjEwytLJObAi3RDzNrsOGJB8x2JP%2FtCIIPiWDhFi78YY3%2B2Wug888WpeCJ6SFFLasFxm%2F6Gg6A0XBpBLsDJuWv93QhrKI6LNA2uefKq0SzwrG3K6Tov4y3eoqmF5vQYa6GKsVYvb0WNTJpPKuGqD5Q0mv23Akfim5CO6R99%2FMtqqKmSDAfjD54KHQaDbCkonA8MQQ9zgf5zFntIkNFoHWJ9xSlT7%2FRKOGnW3L5U3vh75%2BQGXIMi7Q9%2FNYpRttdXyBf1yofoTlNrjLNSobdZSyY5saZt6iXNrX16%2FaVW%2FF2ru101DE1AUkLKJjcLXnN9KFtB04TgNtNnv%2Bp%2BBv57qDU0Yh6wZAQmvTxfnXgw0sXdtcN6cN7aqUy%2BF%2FQ4L8exbR0DaetmxloeW6KF6vtnrM9Z%2BD9AHplRmi1xcaqxNB6yb2QQ5LGJOrKqj4S%2BtWCSpAAnudUrWAZ2aiWltFKr3Fa9u0iJ3jjKOlcmiozqKvBjKCEzj%2BpGgpfTZId6hvk2EwxJ3lzAY6pgEyMc8aEPmwt4Fw1uhyGEsF%2F9ZzNYiTrXXTCRs7OekfaeS1ZK4qampwgjyxWoMsCs%2F4P4EYsbdrradM2USAH3OUhJ0YDDhRcU1UJZLOaK96s8XdJqCoWt%2F9j%2BqxugkRRPsC6R0DN1M5XIQmB6Ksc0NIWGQ9ci%2Blw93e34N7MvJoHf8yZHicRNhd1bzhZxVBoLUxvjKFDqOo%2F%2BrLMptiVsevw8YbBObw&X-Amz-Signature=ca354cc95f72a31f018503d752bce5e411b4074ad4141750eeb5ccf67ca0a505&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)

- **(a)** TWASë¡œ ë³´ê³ ëœ 8ê°œ ìœ ì „ì ì¤‘ AHBAì— ë‚¨ì•„ìˆë˜ 5ê°œ ìœ ì „ìì— ëŒ€í•´ permutation(1000ë²ˆ)ì„ ì‚¬ìš©í•´ subtypeê³¼ì˜ correlation í‰ê°€
	- ë°œê²¬ëœ subtypeâ€‘ê´€ë ¨ ìœ ì „ì(4ê°œ): CCDC24, ELOVL1, TIE1, MED8
	- `Underâ€‘developed`: CCDC24, MED8ì™€ ì–‘ì˜ ìƒê´€; TIE1ì™€ ìŒì˜ ìƒê´€
	- `Overâ€‘developed`: CCDC24, MED8ì™€ ìŒì˜ ìƒê´€
	- `Mixed`: ELOVL1, TIE1ì™€ ì–‘ì˜ ìƒê´€
- **(b)-(d)** 5ê°œ ìœ ì „ìì˜ 2ê°œ PC ì´ìš©í•´ ì¶”ê°€ ë¶„ì„
	- ROI ë³„ Gene expressionìœ¼ë¡œë§Œ PC ê³„ì‚°, ìƒìœ„ 2ê°œì— ëŒ€í•´ ë¶„ì„
	- ROI ë³„ CTê°’ê³¼ PCì˜ ì‚°ì ë„ êµ¬í•¨

<span class="notion-red">_â†’ ë™ì¼í•œ ADHDâ€‘ê´€ë ¨ í›„ë³´ ìœ ì „ìì¡°ì°¨ subtypeë§ˆë‹¤ spatial correlation ë‹¬ë¼ ìœ ì „ì  ê¸°ì§ˆì˜ ì´ì§ˆì„± ì‹œì‚¬._</span>


---



#### Stronger dopamine upregulation in under-developed and mixed subtypes


![](https://prod-files-secure.s3.us-west-2.amazonaws.com/542b861c-36a8-4051-84e5-8804b6728dba/b23fd3d2-7c82-4f9c-9578-378d805f0b5f/image.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=ASIAZI2LB4664CYFHLK6%2F20260221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20260221T091718Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEN%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJGMEQCIC3kJTmJphDNbGIJW3yrJLeiNU3qMj8uyhVJqyHEYq52AiBepVjs%2Bcy5j%2Bxtb9h5R0CcBUa%2B3K%2BKCxQQeu%2B8STT%2FsyqIBAin%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAAaDDYzNzQyMzE4MzgwNSIMJMoSWQqvp8PAfyiKKtwDdekljOY%2B7aZb%2F5dJpTChimF%2FN5YZlRCZd52PKYpKHrvuaIC8h0e7R4Aq7xMBiQQS%2B6HUvY%2B%2BkYNgJfczzvDL4HlnSl2IKbZ5jUh8h%2Flq0GvC3uxZINMdKPs99eaKjEwytLJObAi3RDzNrsOGJB8x2JP%2FtCIIPiWDhFi78YY3%2B2Wug888WpeCJ6SFFLasFxm%2F6Gg6A0XBpBLsDJuWv93QhrKI6LNA2uefKq0SzwrG3K6Tov4y3eoqmF5vQYa6GKsVYvb0WNTJpPKuGqD5Q0mv23Akfim5CO6R99%2FMtqqKmSDAfjD54KHQaDbCkonA8MQQ9zgf5zFntIkNFoHWJ9xSlT7%2FRKOGnW3L5U3vh75%2BQGXIMi7Q9%2FNYpRttdXyBf1yofoTlNrjLNSobdZSyY5saZt6iXNrX16%2FaVW%2FF2ru101DE1AUkLKJjcLXnN9KFtB04TgNtNnv%2Bp%2BBv57qDU0Yh6wZAQmvTxfnXgw0sXdtcN6cN7aqUy%2BF%2FQ4L8exbR0DaetmxloeW6KF6vtnrM9Z%2BD9AHplRmi1xcaqxNB6yb2QQ5LGJOrKqj4S%2BtWCSpAAnudUrWAZ2aiWltFKr3Fa9u0iJ3jjKOlcmiozqKvBjKCEzj%2BpGgpfTZId6hvk2EwxJ3lzAY6pgEyMc8aEPmwt4Fw1uhyGEsF%2F9ZzNYiTrXXTCRs7OekfaeS1ZK4qampwgjyxWoMsCs%2F4P4EYsbdrradM2USAH3OUhJ0YDDhRcU1UJZLOaK96s8XdJqCoWt%2F9j%2BqxugkRRPsC6R0DN1M5XIQmB6Ksc0NIWGQ9ci%2Blw93e34N7MvJoHf8yZHicRNhd1bzhZxVBoLUxvjKFDqOo%2F%2BrLMptiVsevw8YbBObw&X-Amz-Signature=cce771f0f04b3ad0a3fa4823819c3ce23cdf68e8b7110df872cca6af96cbdf84&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)


Neurotransmitter ê´€ë ¨ pathwayê°€ ì¡´ì¬í•œë‹¤ëŠ” ìœ ì „ì  ë°œê²¬ì— ê¸°ë°˜í•´ neurotransmitter profile ì¡°ì‚¬

- Under-developed/mixed subtype ê³¼ ê´€ë ¨
- ABA-ergic synapse, dopaminergic synapse, glutamatergic synapse
- `Under-developed` : Dopamin receptor D1/D2, DAT, GluR5ì™€ ì–‘ì˜ ìƒê´€ê´€ê³„ (r = 0.555, 0.470, 0.566, r = 0.382, P\_{permu}<0.001)
- `Over-developed` : D1, DAT, GluR5ì™€ ìŒì˜ ìƒê´€ê´€ê³„ (r = âˆ’0.316, âˆ’0.407, âˆ’0.181, P\_{permu}<0.001, <0.001, 0.015)
- `Mixed` : D1, DAT, GluR5ì™€ ìŒì˜ ìƒê´€ê´€ê³„( r = âˆ’0.269, âˆ’0.652, âˆ’0.303, P\_{permu} < 0.001)

<span class="notion-red">_â†’ Over-developed/MixedëŠ” ìœ ì‚¬í•œ ìŒì˜ ìƒê´€ê´€ê³„ ë³´ì„_</span>


<span class="notion-red">_â†’ Under-developed/Mixed subtypeì€ Over-developed ë³´ë‹¤ ë” í° ìƒê´€ê´€ê³„ í¬ê¸°ë¥¼ ë³´ì„_</span>


---


---



## Discussion

- Semi-supervised learning method(Smile-GAN)ì„ ì´ìš©í•œ ADHDì˜ heterogenity ë¶„ì„
- ëšœë ·í•œ Cortical thickness profile ê°€ì§€ëŠ” ì„¸ ê°€ì§€ subtype ë¶„ë¥˜
- Under-developed subtypeì€ ê°€ì¥ ë‚®ì€ cognitive scoreë¥¼ ë³´ì´ë©°, í™˜ê²½ì  ìŠ¤íŠ¸ë ˆìŠ¤(ë‚®ì€ ê°€ê³„ ì†Œë“/ë¶€ëª¨ êµìœ¡ ìˆ˜ì¤€)ì™€ ê´€ë ¨ ìˆì„ ìˆ˜ ìˆìŒ
- Over-developed subtypeì€ stimulant medication ë°˜ì‘ì´ ê°€ì¥ ì¢‹ì§€ ì•Šì•˜ê³ , ADHDì˜ ë¹„ì •í˜•ì  íŠ¹ì§•ê³¼ ê´€ë ¨ ìœ ì „ì/ì‹ ê²½ ì „ë‹¬ ë¬¼ì§ˆ ê²½ë¡œì™€ì˜ ë‚®ì€ ìƒê´€ê´€ê³„ì™€ ì—°ê´€ì´ ìˆì„ ìˆ˜ ìˆìŒ

---


---



## Limitations

- AHBAëŠ” ì„±ì¸ HCì˜ ì†Œìˆ˜ sample data â†’ ì—°ë ¹, ì§ˆí™˜ ì°¨ì´ ì¡´ì¬í•¨
